Adomiparin - Momenta Pharmaceuticals
Alternative Names: Adomiparin sodium; M-118Latest Information Update: 06 Oct 2020
Price :
$50 *
At a glance
- Originator Momenta Pharmaceuticals
- Class Antithrombotics; Low molecular weight heparins
- Mechanism of Action Antithrombin III inhibitors; Factor Xa inhibitors; Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute coronary syndromes
Most Recent Events
- 01 Oct 2020 Momenta Pharmaceuticals has been acquired by Johnson & Johnson
- 10 Mar 2011 Adomiparin is available for partnering (http://http://www.momentapharma.com/index.html)
- 02 Nov 2010 Momenta Pharmaceuticals receives a Qualifying Therapeutic Discovery Project grant from the US Government for M 118 development in Acute coronary syndromes